US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

UpStream Bio Inc.

21.86

+0.73003.45%

Post-market: 21.860.00000.00%16:11 EDT

Volume:186.19K

Turnover:4.07M

Market Cap:1.18B

PE:-7.75

High:22.14

Open:21.45

Low:21.44

Close:21.13

52wk High:29.46

52wk Low:5.14

Shares:53.91M

Float Shares:31.42M

Volume Ratio:0.40

T/O Rate:0.59%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8200

EPS(LYR):-5.5835

ROE:-32.49%

ROA:-22.85%

PB:2.88

PE(LYR):-3.92

Loading ...

Overview Company News Filings

Upstream Bio (UPB) Is Up 15.4% After Analyst Upgrades on Verekitug Data Is Sentiment Justified?

Simply Wall St.

Upstream Bio, Inc. (UPB) Receives a Buy from Piper Sandler

Upstream Bio (UPB): Fresh Data and Analyst Coverage Spark New Questions on Valuation

Simply Wall St.

Upstream Bio Initiated at Buy by Truist Securities

Upstream Bio initiated with a Buy at Truist

Why Upstream Bio (UPB) Is Up 6.5% After Positive Phase 2 Results for Verekitug in Respiratory Diseases

Simply Wall St.

HBM Healthcare Investments Reports CHF 236 Million Quarterly Profit, NAV Up 16.4%

Upstream Bio’s verekitug shows prevention of TSLP binding in respiratory disease

Upstream Bio Announces Promising Phase 2 Clinical Results for Verekitug in Severe Respiratory Diseases at ERS Congress

Upstream Bio Inc. to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

Upstream Bio Shares Rise on Positive Data for Sinus-Disease Treatment

Upstream Bio Inc - Verekitug Meets Primary and Secondary Endpoints in Phase 2 Trial

THOMSON REUTERS

Upstream Bio Reports Positive Top-Line Results From the Phase 2 Vibrant Trial of Verekitug for the Treatment of Chronic Rhinosinusitis With Nasal Polyps (Crswnp)

THOMSON REUTERS

Upstream Bio Inc: No Serious Adverse Events (Saes) Observed; Generally Well Tolerated Safety Profile Consistent With Previous Studies

THOMSON REUTERS

Upstream Bio Inc. Announces Upcoming Release of Phase 2 VIBRANT Trial Results for Verekitug in Treating Chronic Rhinosinusitis with Nasal Polyps

Earnings Flash (UPB) Upstream Bio Posts Q2 Net Loss $0.74 a Share, vs. FactSet Est of $0.61 Loss

MT Newswires Live

Upstream Bio Q2 EPS $(0.74) Misses $(0.61) Estimate,

Upstream Bio Q2 Sales $937.00K Beat $317.50K Estimate

Upstream Bio Inc. Reports Widened Net Loss to $40M in Q2 2025, Driven by Increased R&D and Administrative Expenses

Press Release: Fannie Mae Announces Winners of its Latest Non-Performing Loan Sale

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/UPB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"UPB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","market":"US","secType":"STK","nameCN":"UpStream Bio Inc.","latestPrice":21.86,"timestamp":1761336000000,"preClose":21.13,"halted":0,"volume":186192,"hourTrading":{"tag":"盘后","latestPrice":21.86,"preClose":21.86,"latestTime":"16:11 EDT","volume":3314,"amount":72444.04,"timestamp":1761336663247},"delay":0,"floatShares":31417476,"shares":53909427,"eps":-2.819968,"marketStatus":"Market Closed","change":0.73,"latestTime":"10-24 16:00:00 EDT","open":21.45,"high":22.14,"low":21.44,"amount":4074082.0776,"amplitude":0.033128,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.819968,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1761552000000},"marketStatusCode":7,"adr":0,"listingDate":1728619200000,"exchange":"NASDAQ","adjPreClose":21.13,"postHourTrading":{"tag":"盘后","latestPrice":21.86,"preClose":21.86,"latestTime":"16:11 EDT","volume":3314,"amount":72444.04,"timestamp":1761336663247},"volumeRatio":0.40028291881126205,"impliedVol":0.1764,"impliedVolPercentile":0.0244},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","floatShares":31417476,"roa":"-22.85%","roe":"-32.49%","lyrEps":-5.58348,"volumeRatio":0.40028291881126205,"shares":53909427,"dividePrice":0,"high":22.14,"amplitude":0.033128,"preClose":21.13,"low":21.44,"week52Low":5.14,"pbRate":"2.88","psRate":"432.78","week52High":29.4599,"institutionHeld":0,"latestPrice":21.86,"eps":-2.819968,"divideRate":0,"volume":186192,"delay":0,"ttmEps":-2.819968,"open":21.45,"prevYearClose":16.44,"prevWeekClose":20.97,"prevMonthClose":18.81,"prevQuarterClose":18.81,"fiveDayClose":20.97,"twentyDayClose":17.26,"sixtyDayClose":15.31},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/UPB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-06","symbol":"UPB","fiscalQuarterEnding":"2025/03","expectedEps":-0.49,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"pre","actualEps":-0.51},{"market":"US","date":"2025-03-12","symbol":"UPB","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741752000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"UPB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"UPB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.8,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":5,"updateTime":1760500800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/UPB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"UPB","date":"2025-10-24","current":-7.751861,"percent":0.285714,"low":-36.237602,"twenty":-17.908694,"median":-8.694854,"eighty":-7.362988,"high":-5.184222,"avg":-12.062899,"sd":7.576434,"marketCap":1139106192},"quantilePoints":[{"date":"2024-10-11","current":-21.547111,"twenty":-21.096119,"median":-20.419631,"eighty":-19.743142,"marketCap":872808815},{"date":"2024-10-18","current":-29.91246,"twenty":-29.856691,"median":-29.151973,"eighty":-22.814588,"marketCap":1211664002},{"date":"2024-10-25","current":-33.154958,"twenty":-33.128498,"median":-29.931472,"eighty":-28.137991,"marketCap":1343007876},{"date":"2024-10-31","current":-32.943274,"twenty":-33.154958,"median":-32.429578,"eighty":-29.151973,"marketCap":1334433205},{"date":"2024-11-08","current":-35.748083,"twenty":-33.28726,"median":-32.943274,"eighty":-29.633615,"marketCap":1448047598},{"date":"2024-11-15","current":-26.036965,"twenty":-33.27403,"median":-32.40745,"eighty":-26.47861,"marketCap":1390295829},{"date":"2024-11-22","current":-17.866537,"twenty":-33.154958,"median":-29.91246,"eighty":-25.555171,"marketCap":954019497},{"date":"2024-11-29","current":-21.951751,"twenty":-33.154958,"median":-29.151973,"eighty":-21.870823,"marketCap":1172157663},{"date":"2024-12-06","current":-22.082237,"twenty":-33.144374,"median":-26.689395,"eighty":-21.903572,"marketCap":1179125222},{"date":"2024-12-13","current":-20.486294,"twenty":-33.088806,"median":-26.036965,"eighty":-21.589777,"marketCap":1093906626},{"date":"2024-12-20","current":-16.672089,"twenty":-32.969734,"median":-24.742143,"eighty":-20.201232,"marketCap":890239542},{"date":"2024-12-27","current":-19.517686,"twenty":-32.858694,"median":-23.382078,"eighty":-19.472518,"marketCap":1042185906},{"date":"2025-01-03","current":-16.36093,"twenty":-32.784605,"median":-22.553994,"eighty":-19.153329,"marketCap":873624596},{"date":"2025-01-10","current":-16.250519,"twenty":-32.617811,"median":-22.077219,"eighty":-18.486847,"marketCap":867728970},{"date":"2025-01-17","current":-10.92067,"twenty":-31.635576,"median":-21.951751,"eighty":-17.320504,"marketCap":583131018},{"date":"2025-01-24","current":-10.810259,"twenty":-29.950484,"median":-21.600443,"eighty":-16.501454,"marketCap":577235392},{"date":"2025-01-31","current":-11.041119,"twenty":-29.91246,"median":-20.852659,"eighty":-16.230444,"marketCap":589562611},{"date":"2025-02-07","current":-8.561886,"twenty":-29.633615,"median":-19.703378,"eighty":-11.472726,"marketCap":457179006},{"date":"2025-02-14","current":-7.3574,"twenty":-29.151973,"median":-19.472518,"eighty":-10.92067,"marketCap":392863085},{"date":"2025-02-21","current":-8.260764,"twenty":-28.137991,"median":-19.276941,"eighty":-10.810259,"marketCap":441100026},{"date":"2025-02-28","current":-7.839194,"twenty":-27.097043,"median":-19.030874,"eighty":-9.965112,"marketCap":418589453},{"date":"2025-03-07","current":-8.451474,"twenty":-26.562924,"median":-18.338294,"eighty":-8.834903,"marketCap":451283380},{"date":"2025-03-14","current":-7.737899,"twenty":-26.318012,"median":-17.866537,"eighty":-8.491624,"marketCap":485986508},{"date":"2025-03-21","current":-6.875286,"twenty":-26.085144,"median":-16.857781,"eighty":-8.411325,"marketCap":431809204},{"date":"2025-03-28","current":-5.816236,"twenty":-26.012875,"median":-16.36093,"eighty":-8.168077,"marketCap":365294494},{"date":"2025-04-04","current":-5.380659,"twenty":-25.645507,"median":-16.240482,"eighty":-7.936302,"marketCap":337937638},{"date":"2025-04-11","current":-5.466066,"twenty":-24.254326,"median":-13.751211,"eighty":-7.734483,"marketCap":343301728},{"date":"2025-04-17","current":-7.191293,"twenty":-23.886958,"median":-11.472726,"eighty":-7.5722,"marketCap":451656335},{"date":"2025-04-25","current":-7.652492,"twenty":-23.286723,"median":-11.041119,"eighty":-7.514132,"marketCap":480622419},{"date":"2025-05-02","current":-7.693506,"twenty":-22.857123,"median":-10.850408,"eighty":-7.502769,"marketCap":483198327},{"date":"2025-05-09","current":-6.005612,"twenty":-22.499792,"median":-10.810259,"eighty":-7.378434,"marketCap":475536334},{"date":"2025-05-16","current":-5.964849,"twenty":-22.162536,"median":-10.288315,"eighty":-7.189481,"marketCap":472308712},{"date":"2025-05-23","current":-6.324914,"twenty":-22.076215,"median":-9.921951,"eighty":-6.77963,"marketCap":500819374},{"date":"2025-05-30","current":-6.352089,"twenty":-22.02402,"median":-9.013568,"eighty":-6.524152,"marketCap":502971123},{"date":"2025-06-06","current":-7.357554,"twenty":-21.951751,"median":-8.668839,"eighty":-6.524152,"marketCap":582585803},{"date":"2025-06-13","current":-7.853492,"twenty":-21.855392,"median":-8.531773,"eighty":-6.551855,"marketCap":621855206},{"date":"2025-06-20","current":-7.228474,"twenty":-21.688772,"median":-8.441437,"eighty":-6.588317,"marketCap":572364999},{"date":"2025-06-27","current":-7.432284,"twenty":-21.589777,"median":-8.421362,"eighty":-6.683973,"marketCap":588503110},{"date":"2025-07-03","current":-7.60892,"twenty":-21.547111,"median":-8.293047,"eighty":-6.875286,"marketCap":602489473},{"date":"2025-07-11","current":-8.043715,"twenty":-21.219023,"median":-8.229183,"eighty":-7.004282,"marketCap":636917443},{"date":"2025-07-18","current":-7.500221,"twenty":-20.486294,"median":-8.00983,"eighty":-7.116503,"marketCap":593882481},{"date":"2025-07-25","current":-9.06956,"twenty":-20.325696,"median":-7.964314,"eighty":-7.165671,"marketCap":718145935},{"date":"2025-08-01","current":-10.401121,"twenty":-19.703378,"median":-8.043715,"eighty":-7.186764,"marketCap":823581592},{"date":"2025-08-08","current":-8.173881,"twenty":-19.517686,"median":-8.19076,"eighty":-7.191293,"marketCap":853925323},{"date":"2025-08-15","current":-9.608438,"twenty":-19.472518,"median":-8.256445,"eighty":-7.228474,"marketCap":1003793530},{"date":"2025-08-22","current":-9.154334,"twenty":-19.472518,"median":-8.332111,"eighty":-7.228474,"marketCap":956353234},{"date":"2025-08-29","current":-8.648626,"twenty":-19.29215,"median":-8.429698,"eighty":-7.242061,"marketCap":903521996},{"date":"2025-09-05","current":-10.155428,"twenty":-19.267816,"median":-8.442215,"eighty":-7.274671,"marketCap":1060937523},{"date":"2025-09-12","current":-9.247219,"twenty":-19.117195,"median":-8.531282,"eighty":-7.282823,"marketCap":966056931},{"date":"2025-09-19","current":-8.911801,"twenty":-19.040911,"median":-8.561886,"eighty":-7.298422,"marketCap":931015804},{"date":"2025-09-26","current":-8.416414,"twenty":-18.814066,"median":-8.561394,"eighty":-7.303028,"marketCap":879262754},{"date":"2025-10-03","current":-9.592957,"twenty":-18.486847,"median":-8.591998,"eighty":-7.324944,"marketCap":1002176247},{"date":"2025-10-10","current":-10.212191,"twenty":-18.290115,"median":-8.630565,"eighty":-7.351996,"marketCap":1066867560},{"date":"2025-10-17","current":-11.4971,"twenty":-18.113457,"median":-8.648626,"eighty":-7.357523,"marketCap":1201102033},{"date":"2025-10-24","current":-10.903668,"twenty":-17.908694,"median":-8.694854,"eighty":-7.362988,"marketCap":1139106192}],"updateTime":1761442277086},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"UPB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2577938332","title":"Upstream Bio (UPB) Is Up 15.4% After Analyst Upgrades on Verekitug Data Is Sentiment Justified?","url":"https://stock-news.laohu8.com/highlight/detail?id=2577938332","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577938332?lang=en_us&edition=fundamental","pubTime":"2025-10-22 05:19","pubTimestamp":1761081591,"startTime":"0","endTime":"0","summary":"In recent days, several analyst firms reiterated positive ratings on Upstream Bio following promising Phase 2 trial results for its drug candidate verekitug.\nThis heightened attention underscores the potential for verekitug to stand out in the competitive respiratory biologics market, particularly with anticipation surrounding upcoming severe asthma trial outcomes.\nWe'll explore how investor optimism for verekitug's unique potential is shaping Upstream Bio's investment narrative.\nThe end of...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/upstream-bio-upb-is-up-154-after-analyst-upgrades-on-verekit","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/upstream-bio-upb-is-up-154-after-analyst-upgrades-on-verekit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["UPB"],"gpt_icon":0},{"id":"2576852697","title":"Upstream Bio, Inc. (UPB) Receives a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2576852697","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576852697?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:56","pubTimestamp":1760964991,"startTime":"0","endTime":"0","summary":"In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Upstream Bio, Inc., with a price target of $75.00. The com...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/upstream-bio-inc-upb-receives-a-buy-from-piper-sandler-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/upstream-bio-inc-upb-receives-a-buy-from-piper-sandler-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2576432023","title":"Upstream Bio (UPB): Fresh Data and Analyst Coverage Spark New Questions on Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2576432023","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576432023?lang=en_us&edition=fundamental","pubTime":"2025-10-19 07:13","pubTimestamp":1760829230,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) recently made headlines after presenting fresh structural and mechanistic insights for its promising drug candidate, verekitug, at a major scientific congress. This event has drawn renewed investor attention to the company.\nSee our latest analysis for Upstream Bio.\nFollowing the buzz around verekitug’s data, Upstream Bio’s share price has shown real momentum, up nearly 31% over the past month and a striking 96% in the last 90 days. But it’s worth noting the total...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/upstream-bio-upb-fresh-data-and-analyst-coverage-spark-new-q","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/upstream-bio-upb-fresh-data-and-analyst-coverage-spark-new-q","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2575721511","title":"Upstream Bio Initiated at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2575721511","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575721511?lang=en_us&edition=fundamental","pubTime":"2025-10-14 21:19","pubTimestamp":1760447940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UPB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 14, 2025 09:19 ET (13:19 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2575029664","title":"Upstream Bio initiated with a Buy at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2575029664","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575029664?lang=en_us&edition=fundamental","pubTime":"2025-10-14 18:15","pubTimestamp":1760436942,"startTime":"0","endTime":"0","summary":"Truist initiated coverage of Upstream Bio (UPB) with a Buy rating and $47 price target Verekitug offers similarly robust efficacy as other TSLP-rec...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/upstream-bio-initiated-with-a-buy-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/upstream-bio-initiated-with-a-buy-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2574856004","title":"Why Upstream Bio (UPB) Is Up 6.5% After Positive Phase 2 Results for Verekitug in Respiratory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2574856004","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574856004?lang=en_us&edition=fundamental","pubTime":"2025-10-11 02:28","pubTimestamp":1760120883,"startTime":"0","endTime":"0","summary":"At the European Respiratory Society Congress held in Amsterdam from September 27 to October 1, 2025, Upstream Bio presented new structural and mechanistic data for verekitug, highlighting its potent pharmacodynamic activity against the TSLP receptor and positive Phase 2 results in chronic rhinosinusitis with nasal polyps.\nThis advancement, alongside updates on multiple ongoing trials in asthma and COPD, underscores the momentum of Upstream Bio’s clinical pipeline for respiratory...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/why-upstream-bio-upb-is-up-65-after-positive-phase-2-results","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/why-upstream-bio-upb-is-up-65-after-positive-phase-2-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2572535555","title":"HBM Healthcare Investments Reports CHF 236 Million Quarterly Profit, NAV Up 16.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2572535555","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572535555?lang=en_us&edition=fundamental","pubTime":"2025-10-01 23:49","pubTimestamp":1759333787,"startTime":"0","endTime":"0","summary":"Net asset value  per share increased by 16.4% in the second quarter of fiscal year 2025/2026 to CHF 251.78. The company reported a quarterly profit of CHF 236 million, offsetting the currency-related loss from the first quarter. For the first half of the current fiscal year, the company expects a profit of CHF 96 million and an increase in NAV of 6.1% in Swiss francs . The share price rose by 4.0% during the same period and trades at a 28% discount to NAV. The positive second quarter results are mainly attributed to developments in listed portfolio companies, including clinical study results from Abivax, Mineralys, Upstream Bio, and UniQure, as well as acquisition offers for Merus, Y-mAbs Therapeutics, and 89Bio. Foreign currency effects had no material impact on the second quarter's performance. The final half-year results will be published on October 24, 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL5tnLj9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4139","MRUS","QURE","LU0109394709.USD","LU0320765992.SGD","UPB","ETNB","BK4585","YMAB"],"gpt_icon":0},{"id":"2571345035","title":"Upstream Bio’s verekitug shows prevention of TSLP binding in respiratory disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2571345035","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571345035?lang=en_us&edition=fundamental","pubTime":"2025-09-30 18:15","pubTimestamp":1759227319,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) presented structural and mechanistic data showing verekitug’s potent pharmacodynamic activity through its approach of targeting ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/upstream-bios-verekitug-shows-prevention-of-tslp-binding-in-respiratory-disease-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/upstream-bios-verekitug-shows-prevention-of-tslp-binding-in-respiratory-disease-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB","TSLP"],"gpt_icon":0},{"id":"2571731460","title":"Upstream Bio Announces Promising Phase 2 Clinical Results for Verekitug in Severe Respiratory Diseases at ERS Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2571731460","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571731460?lang=en_us&edition=fundamental","pubTime":"2025-09-30 16:15","pubTimestamp":1759220109,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc. , a clinical-stage biotechnology company focused on treatments for inflammatory diseases, has presented new data on its investigational drug verekitug at the European Respiratory Society  Congress 2025. The data highlight verekitug's unique mechanism of action, which involves targeting the thymic stromal lymphopoietin  receptor and preventing TSLP binding by occupying its ligand binding sites. Structural and mechanistic studies reveal that verekitug outcompetes TSLP even in the presence of preformed heterodimeric receptor complexes, supporting its potential for differentiated therapeutic effects in a variety of severe respiratory diseases driven by TSLP. Clinical findings from a recent Phase 2 study in chronic rhinosinusitis with nasal polyps indicate statistically significant and clinically meaningful effects with dosing every 12 weeks. Additional Phase 2 top-line data in severe asthma are expected in the first quarter of 2026. The full presentation is available on t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL2834Y1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","IE00BGHQF748.EUR","BK4139","LU2095319765.USD","LU2210149790.SGD","NDAQ","UPB","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4112"],"gpt_icon":1},{"id":"2566699160","title":"Upstream Bio Inc. to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2566699160","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566699160?lang=en_us&edition=fundamental","pubTime":"2025-09-09 19:00","pubTimestamp":1757415619,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc. , a company focused on developing treatments for inflammatory diseases, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025. The event will feature Rand Sutherland, MD, Chief Executive Officer of Upstream Bio. A live webcast of the chat will be accessible on the company's website, with a replay available after the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on September 09, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL7JPWF0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","LU0314104364.USD","LU2095319765.USD","BK4127","IE00BKPKM429.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","SF","BK4112","IE00B64PRP62.GBP","UPB","NDAQ","LU2210150020.SGD"],"gpt_icon":0},{"id":"2564382331","title":"Upstream Bio Shares Rise on Positive Data for Sinus-Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2564382331","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564382331?lang=en_us&edition=fundamental","pubTime":"2025-09-03 01:56","pubTimestamp":1756835760,"startTime":"0","endTime":"0","summary":"Upstream Bio shares rose after the biotechnology company reported positive results for a trial of a sinus-disease treatment.The stock advanced 7.1% to $18.34 on Tuesday. Shares have gained 12% this year.Results from a Phase 2 trial showed verekitug met the primary endpoint and key secondary endpoints in treating rhinosinusitis with nasal polyps, the Waltham, Mass., clinical-stage company said Tuesday.The trial data showed statistically significant reductions in endoscopic nasal polyp score and nasal congestion score. Treatment with verekitug also resulted in significant reduction in the need for surgery or systemic corticosteroids, Upstream said.The trial was designed to produce data that would support submissions for product approval, Upstream said. The company plans to engage with global regulatory authorities to continue verekitug's development.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Upstream Bio Shares Rise on Positive Data for Sinus-Disease Treatment","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"gpt_icon":1},{"id":"2564880362","title":"Upstream Bio Inc - Verekitug Meets Primary and Secondary Endpoints in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2564880362","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564880362?lang=en_us&edition=fundamental","pubTime":"2025-09-02 18:00","pubTimestamp":1756807201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nTUA3XT8ZV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2564803645","title":"Upstream Bio Reports Positive Top-Line Results From the Phase 2 Vibrant Trial of Verekitug for the Treatment of Chronic Rhinosinusitis With Nasal Polyps (Crswnp)","url":"https://stock-news.laohu8.com/highlight/detail?id=2564803645","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564803645?lang=en_us&edition=fundamental","pubTime":"2025-09-02 18:00","pubTimestamp":1756807201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nTUA3XT8ZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2564803180","title":"Upstream Bio Inc: No Serious Adverse Events (Saes) Observed; Generally Well Tolerated Safety Profile Consistent With Previous Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2564803180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564803180?lang=en_us&edition=fundamental","pubTime":"2025-09-02 18:00","pubTimestamp":1756807201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nTUA3XT8ZV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2564847514","title":"Upstream Bio Inc. Announces Upcoming Release of Phase 2 VIBRANT Trial Results for Verekitug in Treating Chronic Rhinosinusitis with Nasal Polyps","url":"https://stock-news.laohu8.com/highlight/detail?id=2564847514","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564847514?lang=en_us&edition=fundamental","pubTime":"2025-09-02 05:00","pubTimestamp":1756760413,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc. Announces Upcoming Release of Phase 2 VIBRANT Trial Results for Verekitug in Treating Chronic Rhinosinusitis with Nasal Polyps. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on September 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250901:nNDLyXZgH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","IE00BGHQF748.EUR","LU2210150020.SGD","UPB","BK4588"],"gpt_icon":1},{"id":"2557379278","title":"Earnings Flash (UPB) Upstream Bio Posts Q2 Net Loss $0.74 a Share, vs. FactSet Est of $0.61 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2557379278","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557379278?lang=en_us&edition=fundamental","pubTime":"2025-08-06 19:40","pubTimestamp":1754480412,"startTime":"0","endTime":"0","summary":"Earnings Flash (UPB) Upstream Bio Posts Q2 Net Loss $0.74 a Share, vs. FactSet Est of $0.61 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UPB"],"gpt_icon":0},{"id":"2557376258","title":"Upstream Bio Q2 EPS $(0.74) Misses $(0.61) Estimate,","url":"https://stock-news.laohu8.com/highlight/detail?id=2557376258","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557376258?lang=en_us&edition=fundamental","pubTime":"2025-08-06 19:22","pubTimestamp":1754479329,"startTime":"0","endTime":"0","summary":"Upstream Bio Q2 EPS $(0.74) Misses $(0.61) Estimate,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46892729/upstream-bio-q2-eps-0-74-misses-0-61-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB"],"gpt_icon":0},{"id":"2557376933","title":"Upstream Bio Q2 Sales $937.00K Beat $317.50K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2557376933","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557376933?lang=en_us&edition=fundamental","pubTime":"2025-08-06 19:20","pubTimestamp":1754479203,"startTime":"0","endTime":"0","summary":"Upstream Bio Q2 Sales $937.00K Beat $317.50K Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46892616/upstream-bio-q2-sales-937-00k-beat-317-50k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB"],"gpt_icon":0},{"id":"2557376862","title":"Upstream Bio Inc. Reports Widened Net Loss to $40M in Q2 2025, Driven by Increased R&D and Administrative Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2557376862","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557376862?lang=en_us&edition=fundamental","pubTime":"2025-08-06 19:01","pubTimestamp":1754478090,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on August 06, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nNDL10Rs99:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B3QW5Z07.USD","BK4139","IE00BKPKM429.USD","BK4112","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","LU0314104364.USD","UPB","LU2210149790.SGD","BK4585","LU2095319765.USD"],"gpt_icon":0},{"id":"2557318987","title":"Press Release: Fannie Mae Announces Winners of its Latest Non-Performing Loan Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2557318987","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557318987?lang=en_us&edition=fundamental","pubTime":"2025-08-05 23:00","pubTimestamp":1754406000,"startTime":"0","endTime":"0","summary":"WASHINGTON, Aug. 5, 2025 /PRNewswire/ -- Fannie Mae  today announced the results of its twenty-seventh non-performing loan sale transaction. The deal, announced on July 8, 2025, included the sale of 1,304 deeply delinquent loans totaling $285 million in unpaid principal balance , offered in two pools. The winning bidder for Pool 1 was Residential Credit Opportunities Trust X-C, and for Pool 2 was RCF II Loan Acquisition, LP. The transaction is expected to close on September 19, 2025. The deal was marketed with BofA Securities, Inc. as advisor.The loan pools awarded in this most recent transaction include:. -- Pool 1: 332 loans with an aggregate UPB of $73,092,445; average loan size. of $220,158; weighted average note rate of 4.45%; and weighted average. -- Pool 2: 972 loans with an aggregate UPB of $211,965,249; average loan. size of $218,071; weighted average note rate of 4.39%; and weighted. Interested bidders can register for ongoing announcements, training, and other information he","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","R","BK4139","BK4229","FNMA","BK4232","UPB","BK4022"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}]}}